23andMe And Nightingale Health Announce Strategic Collaboration To Pilot Blood Biomarker Panel
ME23andMe (ME) GlobeNewswire News Room·2024-06-28 19:00

SOUTH SAN FRANCISCO, Calif., June 28, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading preventive health and therapeutics company, and Nightingale Health Plc, a pioneer in biomarker testing and risk prediction, today announced a strategic collaboration to pilot Nightingale Health’s clinically-validated and cost-effective blood metabolomics panel with a cohort of 23andMe members. Nightingale’s Remote Health Check accurately measures dozens of biomarkers from a single blood sample, includi ...